Publicacións en colaboración con investigadores/as de Novartis (Sweden) (8)

2024

  1. Activity and safety of eltrombopag in combination with cyclosporin A as first‑line treatment of adults with severe aplastic anaemia (SOAR): a phase 2, single-arm study

    The Lancet Haematology, Vol. 11, Núm. 3, pp. e206-e215

2021

  1. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial

    Rheumatology (United Kingdom), Vol. 60, Núm. 1, pp. 256-262

  2. Secukinumab in patients with psoriatic arthritis and axial manifestations: Results from the double-blind, randomised, phase 3 MAXIMISE trial

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 5, pp. 582-590

2019

  1. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study)

    Oncologist, Vol. 24, Núm. 4, pp. 491-497

2013

  1. Scientific competency questions as the basis for semantically enriched open pharmacological space development

    Drug Discovery Today, Vol. 18, Núm. 17-18, pp. 843-852

  2. Scientific requirements for the next-generation semantic web-based chemogenomics and systems chemical biology molecular information system OPS

    Computational Chemogenomics (Pan Stanford Publishing Pte. Ltd.), pp. 213-242

2011

  1. Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: Results of a 12-week, phase II, dose-finding study

    BMC Musculoskeletal Disorders, Vol. 12

2010

  1. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis

    Science Translational Medicine, Vol. 2, Núm. 52